The protective effect of canagliflozin on renal function in obese patients with T2DM

Trial Profile

The protective effect of canagliflozin on renal function in obese patients with T2DM

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Nov 2016

At a glance

  • Drugs Canagliflozin (Primary)
  • Indications Diabetic nephropathies; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 15 Nov 2016 Status changed from not yet recruiting to recruiting.
    • 04 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top